Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of EGM

3 Jul 2014 11:36

RNS Number : 3708L
ViaLogy PLC
03 July 2014
 



3 July 2014

ViaLogy PLC

("Company")

 

Result of General Meeting

 

The Company announces that, at the General Meeting of the Company held earlier today, all resolutions were duly passed.

 

Accordingly, the following proposals become unconditional in all respects upon Admission of the Enlarged Ordinary Share Capital to trading on AIM, for which application has been made and is expected to occur at 8.00 a.m. on 4 July 2014:

 

· the acquisition by the Company of the entire issued share capital of Premaitha Health Limited, resulting in the admission of 95,454,545 Consideration Shares

 

· the Placing, resulting in the admission of 59,090,909 Placing Shares

 

· the Open Offer, resulting in the admission of 6,723,651 Open Offer Shares

 

· the Share Consolidation, resulting in the Company's Existing Ordinary Share Capital being consolidated into 26,894,601 New Ordinary Shares with a nominal value of 10 pence each

 

· New Board structure:

David Evans - Non-Executive Chairman

Dr Stephen Little - Chief Executive Officer

Peter Collins - Chief Commercial Officer

Mark Collingbourne - Finance Director

Dr Charles Roberts - Non-Executive Director

Adam Reynolds - Non-Executive Director

Nick Mustoe - Non-Executive Director

 

 

The Enlarged Ordinary Share Capital of the Company, comprising 188,163,709 New Ordinary Shares, will trade under the ISIN GB00BN31ZD89.

 

The change of the Company's name to Premaitha Health plc (AIM: NIPT), will become effective upon the registration of the Company's change of name at Companies House. A further announcement will be made in due course.

 

All of the defined terms in this announcement have the same meaning as in the Circular published by the Company and sent to shareholders on 13 June 2014. A copy can also be viewed on the Company's website.

 

 

Total Voting Rights

For the purposes of the Disclosure and Transparency Rules, the total number of voting rights in the Company with effect from 4 July 2014 will be 188,163,709. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

 

 

Enquiries:

 

ViaLogy PLC

Mark Collingbourne

 

 

Tel: +44 1620 810 183

 

Cairn Financial Advisers LLP

Nomad

Liam Murray

Avi Robinson

 

 

 

+44 20 7148 7900

 

Panmure Gordon (UK) Limited

Broker

Robert Naylor

Freddy Crossley

 

+44 20 7886 2500

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
REGLLFVIDEIVIIS
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.